What Fueled The Previous Growth In The Kinase Inhibitors Market?
The kinase inhibitors market has seen considerable growth due to a variety of factors.
• The kinase inhibitors market has seen strong growth in recent years and is projected to expand from $62.75 billion in 2024 to $67.57 billion in 2025, growing at a CAGR of 7.7%.
Contributing factors include the increasing incidence of cancer, advances in targeted therapies, rising healthcare expenditures, the approval of new kinase inhibitors, and the growing use of personalized medicine.
What Is The Expected Growth In The Kinase Inhibitors Market Size Evolve over the Forecast Period?
The kinase inhibitors market is expected to maintain its strong growth trajectory in upcoming years.
• The kinase inhibitors market is projected to grow to $89.57 billion by 2029, with a CAGR of 7.3%.
The growth is driven by continued research and development, the introduction of new kinase inhibitors, expanding uses beyond oncology, increased biotechnology investments, and growing awareness of precision medicine. Key trends include the expansion of precision oncology treatments, the development of combination therapies, a focus on rare and difficult-to-treat cancers, and the increasing use of next-generation sequencing technologies.
What Main Forces Are Fueling Expansion In The Kinase Inhibitors Market?
The rising occurrence of autoimmune diseases is expected to fuel the growth of the kinase inhibitors market. Autoimmune diseases occur when the immune system attacks healthy tissues and organs. Factors like lifestyle changes, environmental pollution, and stress contribute to the increasing prevalence. Kinase inhibitors help treat autoimmune diseases by modulating the immune response and reducing inflammation. In December 2022, the National Psoriasis Foundation reported that over 8 million people in the U.S. suffer from psoriasis, while the CDC reported 28.7 million Americans have diabetes, further driving the demand for kinase inhibitors.
What Are The Primary Segments In The Global Kinase Inhibitors Market?
The kinase inhibitors market covered in this report is segmented –
1) By Type: Tyrosine Kinase Inhibitors, Multikinase Inhibitors, mTOR Kinase Inhibitors, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Application: Oncology, Inflammatory Diseases
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Tyrosine Kinase Inhibitors: EGFR Inhibitors, HER2 Inhibitors, BCR-ABL Inhibitors, Other Tyrosine Kinase Inhibitors
2) By Multikinase Inhibitors: VEGFR Inhibitors, PDGFR Inhibitors, FGFR Inhibitors, Other Multikinase Inhibitors
3) By MTOR Kinase Inhibitors: Everolimus, Temsirolimus, Other MTOR Kinase Inhibitors
4) By Other Types: JAK Inhibitors, ROCK Inhibitors, CDK Inhibitors, Other Kinase Inhibitors
Pre-Book The Kinase Inhibitors Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Kinase Inhibitors Market?
Key players in the kinase inhibitors market are focusing on the creation of selective tyrosine kinase 2 (TYK2) inhibitors to fulfil the growing demand in managing autoimmune and inflammatory diseases. The role of selective tyrosine kinase 2 (TYK2) inhibitors involves regulating immune reactions and mitigating inflammation, aiding in the fight against cancer by boosting the body's mechanism to target and terminate cancer cells, thereby hindering tumor development. As recently as September 2022, the US-based Bristol-Myers Squibb Company was given the green light by the U.S. Food and Drug Administration (FDA) for their product, Sotyktu (deucravacitinib). Sotyktu is an orally administered selective tyrosine kinase 2 (TYK2) inhibitor developed to treat moderate-to-severe plaque psoriasis for adults who are reliant on systemic therapy or phototherapy. The launch of Sotyktu is a notable step forward in the treatment of plaque psoriasis, presenting a fresh alternative for patients who don't react sufficiently to currently available treatments.
Who Are the Key Players In The Kinase Inhibitors Market?
Major companies operating in the kinase inhibitors market are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Bristol-Myers Squibb Company
• AstraZeneca Plc
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Endo International Inc.
• Amneal Pharmaceuticals LLC
• Lupin Limited
• Exelixis Inc.
• Glenmark Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.
• Hutchison China MediTech Limited
• Akorn Incorporated
• Ocular Therapeutix Inc.
• Sierra Oncology Inc
What Is The Most Dominant Region In The Kinase Inhibitors Market?
Asia-Pacific was the largest region in the kinase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
